Reactivation of toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient

被引:35
作者
Baatz, H
Mirshahi, A
Puchta, J
Gümbel, H
Hattenbach, LO
机构
[1] Recklinghausen Eye Ctr, D-45657 Recklinghausen, Germany
[2] Univ Frankfurt, Dept Ophthalmol, D-6000 Frankfurt, Germany
[3] Bundeswehr Hosp Ulm, Ulm, Germany
关键词
atovaquone; retinitis; toxoplasmosis;
D O I
10.1080/09273940600659740
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose : To report a case of toxoplasma retinochoroiditis reactivation in an immunocompetent patient under atovaquone therapy. Methods : Case report. Results : A healthy woman with a history of bilateral toxoplasma retinochoroiditis since childhood presented with a reactivation of toxoplasma retinochoroiditis. Because earlier treatment regimens had either produced intolerable side effects and/or were deemed ineffective for the prevention of reactivation, the patient was started on atovaquone suspension (750 mg three times a day). After initial regression of the lesion and still under atovaquone therapy, the patient presented again five weeks later with worsened best-corrected visual acuity. Examination showed that the lesion had expanded again and more cells were present in the vitreous. Conclusions : To our knowledge, this is the first report of a reactivation of toxoplasma retinochoroiditis in an immunocompetent patient under atovaquone therapy, possibly indicating tachyzoite resistance to atovaquone.
引用
收藏
页码:185 / 187
页数:3
相关论文
共 10 条
[1]   REMARKABLE INVITRO AND INVIVO ACTIVITIES OF THE HYDROXYNAPHTHOQUINONE 566C80 AGAINST TACHYZOITES AND TISSUE CYSTS OF TOXOPLASMA-GONDII [J].
ARAUJO, FG ;
HUSKINSON, J ;
REMINGTON, JS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (02) :293-299
[2]   Antiparasitic agent atovaquone [J].
Baggish, AL ;
Hill, DR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1163-1173
[3]   Treatment of ocular toxaphsmosis with atovaquone in immunocompetent patients [J].
Hudde, T ;
Althaus, C ;
Schimkat, M ;
Sundmacher, R .
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 1996, 209 (04) :232-236
[4]   Central brain atrophy, in childhood AIDS encephalopathy [J].
Scarmato, V ;
Frank, Y ;
Rozenstein, A ;
Lu, DF ;
Hyman, R ;
Bakshi, S ;
Pahwa, S ;
Pavlakis, S .
AIDS, 1996, 10 (11) :1227-1231
[5]   Molecular basis for atovaquone binding to the cytochrome bc1 complex [J].
Kessl, JJ ;
Lange, BB ;
Merbitz-Zahradnik, T ;
Zwicker, K ;
Hill, P ;
Meunier, B ;
Pálsdóttir, H ;
Hunte, C ;
Meshnick, S ;
Trumpower, BL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (33) :31312-31318
[6]   Toxoplasmosis, an overview with emphasis on ocular involvement [J].
Klaren, VNA ;
Kijlstra, A .
OCULAR IMMUNOLOGY AND INFLAMMATION, 2002, 10 (01) :1-26
[7]   ORALLY-ADMINISTERED 566C80 FOR TREATMENT OF OCULAR TOXOPLASMOSIS IN A PATIENT WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
LOPEZ, JS ;
DESMET, MD ;
MASUR, H ;
MUELLER, BU ;
PIZZO, PA ;
NUSSENBLATT, RB .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1992, 113 (03) :331-333
[8]   Characterization of cytochrome b from Toxoplasma gondii and Qo domain mutations as a mechanism of atovaquone-resistance [J].
McFadden, DC ;
Tomavo, S ;
Berry, EA ;
Boothroyd, JC .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2000, 108 (01) :1-12
[9]   Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients [J].
Pearson, PA ;
Piracha, AR ;
Sen, HA ;
Jaffe, GJ .
OPHTHALMOLOGY, 1999, 106 (01) :148-153
[10]   IN-VITRO AND IN-VIVO ACTIVITIES OF THE HYDROXYNAPHTHOQUINONE ATOVAQUONE ALONE OR COMBINED WITH PYRIMETHAMINE, SULFADIAZINE, CLARITHROMYCIN, OR MINOCYCLINE AGAINST TOXOPLASMA-GONDII [J].
ROMAND, S ;
PUDNEY, M ;
DEROUIN, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (11) :2371-2378